Overview

Phase 1 Study for IPG11406 in Health Volunteer

Status:
RECRUITING

Trial end date:
2025-04-30

Target enrollment:

Participant gender:

Summary

A phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and food effect of orally administered IPG11406 in healthy adult participants

Phase:

PHASE1

Details

Lead Sponsor:

Nanjing Immunophage Biotech Co., Ltd

Collaborator:

Zhejiang Hospital